Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer.

Shang, Jiuyan; Sun, Xuemei; Xu, Zihang; Cai, Lijing; Liu, Chang; Wu, Si; Liu, Yueping

Shang, Jiuyan; Sun, Xuemei; Xu, Zihang; Cai, Lijing; Liu, Chang; Wu, Si; Liu, Yueping.

Afiliación

Shang J; Department of Pathology, Hebei Medical University, The Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, China.
Sun X; Department of Pathology, Hebei Medical University, The Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, China.
Xu Z; Anesthesia Class, School of Basic Medicine, Hebei Medical University, Shijiazhuang, China.
Cai L; Department of Pathology, Hebei Medical University, The Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, China.
Liu C; Department of Pathology, Hebei Medical University, The Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, China.
Wu S; Department of Pathology, Hebei Medical University, The Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, China.
Liu Y; Department of Pathology, Hebei Medical University, The Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Shijiazhuang, China.

Front Oncol ; 13: 1086480, 2023.

Article en En | MEDLINE | ID: mdl-36910643

Palabras clave

breast cancer; hormone receptor; human epidermal growth factor receptor 2; neoadjuvant therapy; pathological complete response

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google